

NCT ID	NCT04730544
Title	Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer (NIPISAFE)
Phase	Phase 2
Date Added	2021-01-29
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab
Tags	MSI-H/ MMRd
NCT ID	NCT04724239
Title	A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase	Phase 2
Date Added	2021-01-26
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	chidamide, IBI305, Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT04708470
Title	Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
Phase	Phase 1, Phase 2
Date Added	2021-01-14
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bintrafusp alfa, Entinostat, NHS-IL12
Tags	MSS/ MMRp
NCT ID	NCT04687631
Title	Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Phase	Phase 3
Date Added	2020-12-29
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04660812
Title	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Phase	Phase 1, Phase 2

Date Added	2020-12-09
Location	Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy South Korea Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Completed
Drugs	AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab
Tags	MSS/ MMRp
NCT ID	NCT04659382
Title	Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2020-12-09
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, TheraSphere, XELOX
Tags	MSS/ MMRp
NCT ID	NCT04653480
Title	Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Phase	Phase 2
Date Added	2020-12-04
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy, Surufatinib, Toripalimab
Tags	MSS/ MMRp
NCT ID	NCT04626635
Title	REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-11-12

Location	California, United States
	Colorado, United States
	Florida, United States
	Illinois, United States
	Iowa, United States
	Massachusetts, United States
	Michigan, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Pennsylvania, United States
	Tennessee, United States
	Texas, United States
	Washington, United States
	Wisconsin, United States
	France
	Israel
	Netherlands
	Poland
	Spain
	Turkey (Türkiye)
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	cemiplimab, REGN7075
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04607421
Title	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
Phase	Phase 3
Date Added	2020-10-29

Location	Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT04599140
Title	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
Phase	Phase 1, Phase 2
Date Added	2020-10-22
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting

Drugs

CXCR1/2 Inhibitor SX-682, Nivolumab

Tags

MSS/ MMRp